Delcath Systems Gestione
Criteri Gestione verificati 3/4
Delcath Systems Il CEO è Gerard Michel, nominato in Oct2020, e ha un mandato di 5.58 anni. la retribuzione annua totale è $ 5.77M, composta da 11% di stipendio e 89% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.99% delle azioni della società, per un valore di $ 3.77M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.9 anni e 6 anni.
Informazioni chiave
Gerard Michel
Amministratore delegato
US$5.8m
Compenso totale
| Percentuale dello stipendio del CEO | 11.03% |
| Mandato del CEO | 5.6yrs |
| Proprietà del CEO | 1.0% |
| Durata media del management | 2.9yrs |
| Durata media del Consiglio di amministrazione | 6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Apr 30
DCTH: 2026 Spend Increase Will Drive Hepatic Cancer Therapy Adoption
Analysts have trimmed their blended price target on Delcath Systems by about $2 to align with recent Street research that lowered the target to $27, citing updated FY26 sales guidance of at least $100m and sharply higher planned R&D and SG&A spending to support HEPZATO commercial and label expansion efforts. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$27 price target as still reflecting upside potential relative to current trading levels, even after trimming expectations.Aggiornamento della narrazione • Apr 16
DCTH: 2026 Spend Increase Will Support Hepatic Cancer Therapy Expansion
Analysts trimmed their price target on Delcath Systems to $27 from $29, citing updated guidance for at least $100M in FY26 sales and a very large projected increase in R&D and SG&A spending to support the HEPZATO label and commercial expansion. Analyst Commentary Recent commentary focuses on how the updated FY26 sales outlook and higher operating spend could affect the risk and reward profile for Delcath Systems, especially around execution on HEPZATO and future label opportunities.
Aggiornamento della narrazione • Apr 02
DCTH: Higher 2026 Spending Will Support Liver Cancer Therapy Expansion
Analysts have trimmed their average price target on Delcath Systems by $2, citing recent FY25 results, updated FY26 sales guidance of at least $100M versus prior consensus of $111M, and expectations for higher R&D and SG&A spending to support HEPZATO growth and label expansion. Analyst Commentary Recent Street commentary on Delcath Systems centers on how near term spending and updated sales guidance could affect the risk and reward profile for shareholders.Aggiornamento della narrazione • Mar 18
DCTH: Higher 2026 Spending Will Support Cancer Therapy Cash Flows And Expansion
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been trimmed by $2 to $27, as analysts factor in the company's FY26 sales guidance of at least $100M, along with sharply higher planned R&D and SG&A spending to support HEPZATO and label expansion. Analyst Commentary Recent research updates on Delcath Systems highlight a mixed reaction to the company’s outlook, with particular attention on FY26 guidance and the spending required to support HEPZATO and label expansion.Aggiornamento della narrazione • Mar 04
DCTH: Higher 2026 Spending Will Support Future Revenue Expansion Potential
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been reduced by $3 to $27. Analysts point to updated FY26 sales guidance of at least $100M and significantly higher projected R&D and SG&A spending to support HEPZATO growth and label expansion as key factors behind the change.Aggiornamento della narrazione • Feb 18
DCTH: Steadier Cancer Therapy Cash Flows Will Support Future Indication Expansion
Analysts have raised their price target on Delcath Systems by $1 to $29, citing preliminary Q4 results that indicate Hepzato is becoming a more stable revenue contributor, with more predictable quarter-to-quarter trends and cash flow that may support expansion plans. Analyst Commentary Analysts highlighting the new US$29 price target point to Hepzato’s role as a steadier revenue source and to cash flow that may help support future expansion plans.Aggiornamento della narrazione • Feb 04
DCTH: Steadier Liver Cancer Therapy Revenues Will Support Future Indication Expansion
Analysts have nudged their price target on Delcath Systems higher to $29 from $28, pointing to Hepzato's role as a steady revenue contributor with more predictable quarter to quarter variability and cash flow that can support expansion of additional indications. Analyst Commentary Even with the higher price target, not all commentary around Delcath Systems leans positive.Aggiornamento della narrazione • Jan 20
DCTH: Steadier Hepatic Therapy Uptake Will Support Future Expansion Plans
Analysts recently lifted their price target on Delcath Systems to $29 from $28, citing Hepzato's role as a steadier and more predictable contributor to revenue and cash flow. They believe this supports potential expansion plans and informs modest adjustments to growth, margin, and future P/E assumptions.Aggiornamento della narrazione • Jan 06
DCTH: CHOPIN Trial Data Will Support Future Uptake Despite Softer Guidance
Analysts have kept their fair value estimate for Delcath Systems steady at $18.00 while adjusting underlying assumptions, citing mixed reactions to softer Q3 and FY2025 revenue guidance alongside supportive CHOPIN trial data and a range of updated price targets from $20 to $30. Analyst Commentary Street research on Delcath Systems has centered on the tension between supportive CHOPIN trial data and softer near term revenue guidance, with several price target revisions reflecting this mixed setup.Aggiornamento della narrazione • Dec 14
DCTH: CHOPIN Data Expected To Drive Stronger Uptake Despite Near-Term Guidance Reset
Analysts have trimmed their fair value estimate for Delcath Systems to $18.00 from $21.00, reflecting lower near term revenue growth assumptions after soft preliminary guidance. This comes despite sustained confidence in Hepzato uptake driven by positive CHOPIN trial data and improving profit margin expectations.Articolo di analisi • Nov 21
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge
The Delcath Systems, Inc. ( NASDAQ:DCTH ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Nov 06
Delcath: Temporary Headwinds Are No Cause For Concern
Summary Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time. Delcath's valuation is extremely low given the prospect of continued growth and strong margins once growth investments normalize. Read the full article on Seeking AlphaArticolo di analisi • Oct 28
The Delcath Systems, Inc. (NASDAQ:DCTH) Analysts Have Been Trimming Their Sales Forecasts
The latest analyst coverage could presage a bad day for Delcath Systems, Inc. ( NASDAQ:DCTH ), with the analysts making...Articolo di analisi • Aug 09
Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next
NasdaqCM:DCTH 1 Year Share Price vs Fair Value Explore Delcath Systems's Fair Values from the Community and select...Articolo di analisi • Jul 12
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 29% Share Price Plunge
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 29% in the last month, reversing a fair...Articolo di analisi • Jun 18
Delcath Systems (NASDAQ:DCTH) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Articolo di analisi • May 22
Delcath Systems, Inc.'s (NASDAQ:DCTH) 52% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders would be excited to see that the share price has had a great month...Articolo di analisi • May 11
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, Delcath Systems, Inc. ( NASDAQ:DCTH ) came out with a strong set of first-quarter numbers that could...
Nuova narrazione • May 02
HEPZATO Launch And European Expansion Will Expand Treatment Access
Expansion in U.S. treatment centers and commercial teams is expected to drive significant revenue growth and improve operational efficiencies.Articolo di analisi • Mar 11
With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 27% in the last month, reversing a fair...Articolo di analisi • Jan 18
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 31% Share Price Bounce
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders have had their patience rewarded with a 31% share price jump in the...Articolo di analisi • Dec 19
Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Nov 18
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Summary Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors. Despite promising trends, investors should be cautious of seasonality impacts and the risks associated with upcoming Phase II trials and increased R&D expenses. I take a look at the charts to see if I can identify an opportunity to add to my position. Read the full article on Seeking AlphaArticolo di analisi • Nov 01
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Despite an already strong run, Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have been powering on, with a gain of 26...Articolo di analisi • Sep 10
Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have continued their recent momentum with a 26% gain in the last month...Articolo di analisi • Aug 27
Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Aug 07
Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Delcath Systems, Inc. ( NASDAQ:DCTH ) filed its quarterly result this time last...Articolo di analisi • Jan 15
Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$561k |
| Dec 31 2025 | US$6m | US$636k | US$3m |
| Sep 30 2025 | n/a | n/a | US$1m |
| Jun 30 2025 | n/a | n/a | US$2m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$2m | US$561k | -US$26m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$56m |
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$3m | US$538k | -US$48m |
| Sep 30 2023 | n/a | n/a | -US$45m |
| Jun 30 2023 | n/a | n/a | -US$34m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$1m | US$521k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$2m | US$475k | -US$26m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$6m | US$113k | -US$24m |
Compensazione vs Mercato: La retribuzione totale di Gerard ($USD 5.77M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.64M ).
Compensazione vs guadagni: La retribuzione di Gerard è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Gerard Michel (62 yo)
5.6yrs
Mandato
US$5,765,258
Compensazione
Mr. Gerard J. Michel, MS, MBA, is an Independent Director of Beta Bionics, Inc. from March 26, 2025. Mr. Michel serves as Chief Executive Officer and Director at Delcath Systems Inc since October 1, 2020....
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$5.77m | 0.99% $ 3.8m | |
| Chief Operating Officer | 2.2yrs | US$2.02m | 0.022% $ 84.5k | |
| Chief Medical Officer | 2.9yrs | US$2.06m | 0.49% $ 1.9m | |
| Chief Financial Officer | 2.9yrs | Nessun dato | 0.22% $ 848.7k | |
| General Counsel | 4.3yrs | Nessun dato | 0.25% $ 942.9k | |
| Senior Vice President of Clinical Operations & Medical Affairs | 5.3yrs | US$737.50k | Nessun dato | |
| Chief Commercial Officer | less than a year | US$1.02m | 0.071% $ 268.7k | |
| Senior Vice President of Interventional Oncology | 1.2yrs | Nessun dato | Nessun dato |
2.9yrs
Durata media
56.5yo
Età media
Gestione esperta: Il team dirigenziale di DCTH è considerato esperto (durata media dell'incarico 2.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$5.77m | 0.99% $ 3.8m | |
| Independent Director | 6.3yrs | US$306.22k | 0% $ 0 | |
| Independent Director | 6yrs | US$306.22k | 0.24% $ 905.8k | |
| Independent Chairman | 6.8yrs | US$337.64k | 0.043% $ 164.6k | |
| Independent Director | 6yrs | US$293.72k | 0.15% $ 566.2k | |
| Director | 2yrs | US$301.22k | 0% $ 0 |
6.0yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DCTH sono considerati esperti (durata media dell'incarico 6 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/26 17:58 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Delcath Systems, Inc. è coperta da 12 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |
| John Newman | Canaccord Genuity |